Sarepta Reports Positive Phase 3 EMBARK Data For Elevidys In Duchenne Muscular Dystrophy
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...
Investing1h
Roche's Elevidys shows sustained benefits in DMD study
Roche on Monday revealed positive results from the EMBARK trial, showing that its gene therapy Elevidys has sustained benefits for individuals with Duchenne muscular dystrophy (DMD) over a two-year ...
Ryanair beats profit forecast on improving fares, trims traffic outlook
Ryanair reported after-tax profit for the three months to the end of December ahead of analyst forecasts on Monday, but ...
Reminisce on taking the Polar Plunge
Watch the sunset from Cunningham Lake on May 29, 2024 If you’ve ever wanted to take a dead-of-winter swim in subfreezing ...